Nebraska's four licensed medical cannabis cultivators are confronting a potential two-year wait before they can sell products, prompting urgent calls for state regulators to overhaul testing requirements and fee structures.
The delay threatens to undermine Nebraska's nascent medical cannabis program before it even launches. Voters approved medical marijuana in November 2022, but the state's regulatory framework has created bottlenecks that growers say are financially unsustainable.
The cultivators are pressing the Nebraska Department of Health and Human Services to revise testing protocols they argue are overly burdensome compared to other state programs. Industry sources familiar with the matter say the current requirements could force multiple rounds of testing that add months to the cultivation-to-sale timeline.
The Fee Problem
Beyond testing, the licensed growers are challenging Nebraska's fee structure. While specific fee amounts weren't disclosed, operators in newly launched medical programs typically face application fees ranging from $5,000 to $100,000, plus annual renewal costs and per-plant or per-square-foot cultivation fees.
The combination of high upfront costs and delayed revenue has put Nebraska's four cultivators in a financial squeeze. Unlike established markets where operators can achieve cash flow within months, Nebraska growers must continue investing in facilities, security, and compliance without any product sales on the horizon.
This situation mirrors challenges seen in other states with slow-rolling medical programs. Ohio's medical cannabis operators faced similar delays in 2018-2019, with some cultivators spending over $1 million before selling their first gram.
What Happens Next
The cultivators are actively engaging with state regulators to negotiate changes before the two-year timeline becomes reality. Any revisions to testing rules would likely require formal rulemaking processes, which can take several months.
Nebraska's medical cannabis program serves patients with qualifying conditions including cancer, glaucoma, and PTSD. The state has yet to announce when dispensaries will open or when the first legal sales will occur.
For now, the four licensed cultivators are in a holding pattern, maintaining their facilities and compliance infrastructure while advocating for regulatory relief. The outcome of their negotiations with state health officials will determine whether Nebraska's medical program launches in 2025 or gets pushed into 2026 or beyond.
This article is based on original reporting by mjbizdaily.com.
